These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19550290)

  • 1. HIV, the brain, children, HAART and 'neuro-HAART': a complex mix.
    Brew BJ
    AIDS; 2009 Sep; 23(14):1909-10. PubMed ID: 19550290
    [No Abstract]   [Full Text] [Related]  

  • 2. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired neurocognition in HIV-infected patients: antecedents and treatment.
    Fessel WJ
    AIDS; 2009 Aug; 23(13):1731-3. PubMed ID: 19574882
    [No Abstract]   [Full Text] [Related]  

  • 4. [HIV associated encephalopathy after highly active antiretroviral therapy (HAART)].
    Kishida S
    No To Shinkei; 2004 Apr; 56(4):301-10. PubMed ID: 15237721
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.
    Sacktor N; Nakasujja N; Skolasky R; Robertson K; Wong M; Musisi S; Ronald A; Katabira E
    Neurology; 2006 Jul; 67(2):311-4. PubMed ID: 16864825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit or toxicity from neurologically targeted antiretroviral therapy?
    Brew BJ
    Clin Infect Dis; 2010 Mar; 50(6):930-2. PubMed ID: 20146628
    [No Abstract]   [Full Text] [Related]  

  • 7. [Neurological manifestations of HIV-infection in the era of highly active antiretroviral therapy (HAART)].
    Arendt G
    Fortschr Neurol Psychiatr; 2005 Oct; 73(10):577-86. PubMed ID: 16217698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy.
    Carvalhal AS; Rourke SB; Belmonte-Abreu P; Correa J; Goldani LZ
    Infection; 2006 Dec; 34(6):357-60. PubMed ID: 17180595
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
    Cysique LA; Maruff P; Brew BJ
    Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoting successful cognitive aging in adults with HIV: strategies for intervention.
    Vance DE; Burrage JW
    J Gerontol Nurs; 2006 Nov; 32(11):34-41. PubMed ID: 17112136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment: treatment of HIV-associated cognitive impairment--beyond HAART.
    Parsons TD; Robertson KR
    AIDS Read; 2005 Jun; 15(6):293. PubMed ID: 15962452
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New spectrum of HIV-associated cognitive disorders in the HAART era].
    Du Pasquier R; Cavassini M; Simioni S; Annoni JM; Giacobini E; Hirschel B
    Rev Med Suisse; 2009 Apr; 5(201):955-6, 958-61. PubMed ID: 19476058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 associated dementia: symptoms and causes.
    Ghafouri M; Amini S; Khalili K; Sawaya BE
    Retrovirology; 2006 May; 3():28. PubMed ID: 16712719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Gattinara GC; Esposito S; Viganò A; Giaquinto C; Rosso R; Guarino A; de Martino M
    AIDS; 2007 Jul; 21(12):1607-15. PubMed ID: 17630556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive outcomes in pediatric HIV.
    Willen EJ
    Ment Retard Dev Disabil Res Rev; 2006; 12(3):223-8. PubMed ID: 17061290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurocognitive changes in the HAART era. Neuro-AIDS noticeably moves into focus].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():41-2. PubMed ID: 19031562
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART).
    Chiriboga CA; Fleishman S; Champion S; Gaye-Robinson L; Abrams EJ
    J Pediatr; 2005 Mar; 146(3):402-7. PubMed ID: 15756229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy.
    Mitchell CD
    Ment Retard Dev Disabil Res Rev; 2006; 12(3):216-22. PubMed ID: 17061285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.